nach oben

International Urology and Nephrology

Erschienen in:

29.12.2017 | Urology - Original Paper

Anticancer activity of Schiff base–Poloxamer P85 combination against kidney cancer

verfasst von: Ayşegül Doğan, Selami Demirci, Dilek Telci, Serli Canikyan, Merve Kongur, Bülent Dede, Fikrettin Şahin

Erschienen in: International Urology and Nephrology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Renal cell carcinoma (RCC) accounts for approximately 80% of the primary renal cancers, and current treatment strategies are not sufficient to provide a certain solution. Since there are not many treatment options, interest in discovery of alternative drugs has increased.

Methods

In the current study, anticancer activity of a novel heterodinuclear Cu(II)–Mn(II) complex (Schiff base—SB) in combination with poly(ethylene oxide) and poly(propylene oxide) block copolymer (pluronic) P85 was tested against RCC. Cell viability, apoptosis and gene expression analysis were conducted in vitro by using Renca cells.

Results

The results revealed that the SB–P85 combination decreased cell proliferation by increasing the apoptotic gene expressions and apoptosis. Renca-injected BALB/c mice were used to mimic early stage of RCC model. Treatment with SB–P85 combination suppressed tumor formation and growth compared to baseline.

Conclusion

Overall, SB–P85 showed promising anticancer activity against RCC in vitro and in vivo.

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA Cancer J Clin 66(1):7–30CrossRefPubMed

Chauhan A, Semwal DK, Mishra SP, Goyal S, Marathe R, Semwal RB (2016) Combination of mTOR and MAPK ınhibitors—a potential way to treat renal cell carcinoma. Med Sci 4(4):16

Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13(3):688–696CrossRefPubMed

MRCRC Collaborators (1999) Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353(9146):14–17CrossRef

Van Spronsen D, De Weijer K, Mulders P, De Mulder P (2005) Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anticancer Drugs 16(7):709–717CrossRefPubMed

Yuan Z-X, Mo J, Zhao G, Shu G, Fu H-L, Zhao W (2016) Targeting strategies for renal cell carcinoma: from renal cancer cells to renal cancer stem cells. Front Pharmacol 7(423):1–15

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134CrossRefPubMed

Cho YH, Kim MS, Chung HS, Hwang EC (2017) Novel immunotherapy in metastatic renal cell carcinoma. Investig Clin Urol 58(4):220–227CrossRefPubMedPubMedCentral

Prakash A, Adhikari D (2011) Application of Schiff bases and their metal complexes-a review. Int J Chem Tech Res 3(4):1891–1896

10.

Brown D, Smith W, Teape J, Lewis A (1980) Antiinflammatory effects of some copper complexes. J Med Chem 23(7):729–734CrossRefPubMed

11.

Turan-Zitouni G, Sıvacı D, Kaplancıklı Z, Özdemir A (2002) Synthesis and antimicrobial activity of some pyridinyliminothiazoline derivatives. Il Farm 57(7):569–572CrossRef

12.

Baul TSB, Basu S, de Vos D, Linden A (2009) Amino acetate functionalized Schiff base organotin (IV) complexes as anticancer drugs: synthesis, structural characterization, and in vitro cytotoxicity studies. Investig New Drugs 27(5):419CrossRef

13.

Duff B, Thangella VR, Creaven BS, Walsh M, Egan DA (2012) Anti-cancer activity and mutagenic potential of novel copper(II) quinolinone Schiff base complexes in hepatocarcinoma cells. Eur J Pharmacol 689(1):45–55CrossRefPubMed

14.

Demirci S, Doğan A, Başak N, Telci D, Dede B, Orhan C, Tuzcu M, Şahin K, Şahin N, Özercan İH (2015) A Schiff base derivative for effective treatment of diethylnitrosamine-induced liver cancer in vivo. Anticancer Drugs 26(5):555–564CrossRefPubMed

15.

Dogan A, Basak N, Demirci S, Telci D, Dede B, Tuzcu M, Ozercan IH, Sahin K, Sahin F (2014) A novel Schiff base derivative for effective treatment of azoxymethane induced colon cancer. Int J Pharm Sci Res 5(8):3544

16.

Kabanov AV, Nazarova IR, Astafieva IV, Batrakova EV, Alakhov VY, Yaroslavov AA, Kabanov VA (1995) Micelle formation and solubilization of fluorescent probes in poly (oxyethylene-b-oxypropylene-b-oxyethylene) solutions. Macromolecules 28(7):2303–2314CrossRef

17.

Batrakova EV, Han H-Y, Miller DW, Kabanov AV (1998) Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells. Pharm Res 15(10):1525–1532CrossRefPubMed

18.

Dede B, Karipcin F, Cengiz M (2009) Novel homo-and hetero-nuclear copper(II) complexes of tetradentate Schiff bases: synthesis, characterization, solvent-extraction and catalase-like activity studies. J Hazard Mater 163(2):1148–1156CrossRefPubMed

19.

Demirci S, Doğan A, Karakuş E, Halıcı Z, Topçu A, Demirci E, Sahin F (2015) Boron and poloxamer (F68 and F127) containing hydrogel formulation for burn wound healing. Biol Trace Elem Res 168(1):169–180CrossRefPubMed

20.

Demirci S, Doğan A, Apdik H, Tuysuz EC, Gulluoglu S, Bayrak OF, Şahin F (2017) Cytoglobin inhibits migration through PI3 K/AKT/mTOR pathway in fibroblast cells. Mol Cell Biochem. https://doi.org/10.1007/s11010-017-3101-2 PubMed

21.

Doğan A, Demirci S, Şahin F (2015) In vitro differentiation of human tooth germ stem cells into endothelial-and epithelial-like cells. Cancer Cell Int 39(1):39–103

22.

Iguchi M, Matsumoto M, Hojo K, Wada T, Matsuo Y, Arimura A, Abe K (2009) Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma. Jpn J Clin Oncol 39(5):303–309CrossRefPubMed

23.

Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24(3):148–154CrossRefPubMed

24.

Demirci S, Dogan A, Türkmen NB, Telci D, Çaglayan AB, Beker MÇ, Kiliç E, Özkan F, Dede B, Sahin F (2017) Poloxamer P85 increases anticancer activity of Schiff base against prostate cancer in vitro and in vivo. Anticancer Drugs 28(8):869–879CrossRefPubMed

25.

Demirci S, Doğan A, Türkmen NB, Telci D, Rizvanov AA, Şahin F (2017) Schiff base-Poloxamer P85 combination demonstrates chemotherapeutic effect on prostate cancer cells in vitro. Biomed Pharmacother 86:492–501CrossRefPubMed

26.

Doğan A, Demirci S, Türkmen NB, Çağlayan AB, Aydın S, Telci D, Kılıç E, Şahin K, Orhan C, Tuzcu M (2016) Schiff base-poloxamer P85 combination prevents prostate cancer progression in C57/Bl6 mice. Prostate 76(15):1454–1463CrossRefPubMed

27.

Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353(23):2477–2490CrossRefPubMed

28.

Alexandridis P, Lindman B (2000) Amphiphilic block copolymers: self-assembly and applications. Elsevier, Amsterdam

29.

Doğan A, Yalvaç ME, Şahin F, Kabanov AV, Palotás A, Rizvanov AA (2012) Differentiation of human stem cells is promoted by amphiphilic pluronic block copolymers. Int J Nanomed 7:4849

Titel: Anticancer activity of Schiff base–Poloxamer P85 combination against kidney cancer
verfasst von: Ayşegül Doğan
Selami Demirci
Dilek Telci
Serli Canikyan
Merve Kongur
Bülent Dede
Fikrettin Şahin
Publikationsdatum: 29.12.2017
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 2/2018
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-017-1782-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Acute kidney injury after abdominal aortic aneurysm repair: current epidemiology and potential prevention

Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies

Clinicopathological study of male and female patients with lupus nephritis: a retrospective study

The effectiveness of multidisciplinary care models for patients with chronic kidney disease: a systematic review and meta-analysis

What is the place of POEMS syndrome in the current classification of monoclonal gammopathies of renal significance?